相似文献/References:
[1]田梦媛,殷 潇,张欲晓,等.吉非替尼治疗晚期非小细胞肺癌的医保预算影响分析[J].卫生经济研究,2016,(12):25.
[2]陈平钰,李洪超,马爱霞.直接抗病毒药物治疗慢性丙型肝炎患者的预算影响分析[J].卫生经济研究,2019,(01):44.
CHEN Ping-yu,LI Hong-chao,MA Ai-xia.Budgetary Impact Analysis of Direct Antiviral Drugs in the treatment of Patients with Chronic Hepatitis C[J].Journal Press of Health Economics Research,2019,(06):44.
[3]杜 怿,李 灿,方 刚,等.医保药物经济性评价质量评估量表研究及启示[J].卫生经济研究,2020,(06):28.
DU Yi,LI Can,FANG Gang,et al.Research and Enlightenment of Quality Assessment Scale for Medical Insurance Drugs' Economic Evaluation[J].Journal Press of Health Economics Research,2020,(06):28.
[4]柳鹏程,李 灿,杜 怿,等.中国医保预算影响分析的研究范式[J].卫生经济研究,2021,38(1):40.
LIU Peng-cheng,LI Can,DU Yi,et al.Research Paradigm of Impact Analysis on Medical Insurance Budget in China[J].Journal Press of Health Economics Research,2021,38(06):40.
[5]何 达,顾一纯,汪 茹,等.全球手术机器人产业发展动向及启示[J].卫生经济研究,2025,42(02):16.
HE Da,GU Yichun,WANG Ru,et al.Development Trends and Implications of Global Surgical Robot Industry[J].Journal Press of Health Economics Research,2025,42(06):16.